医療科学部

東本 祐紀

ヒガシモト ユウキ  (higashimoto yuki)

基本情報

所属
藤田医科大学 医療科学部 細胞機能解析学分野 講師
学位
医学博士(藤田保健衛生大学)

研究者番号
20569701
J-GLOBAL ID
201801012069684307
researchmap会員ID
7000023878

論文

 37
  • Ayami Yoshikane, Hiroki Miura, Sayuri Shima, Masaaki Matsunaga, Soichiro Ishimaru, Yuki Higashimoto, Yoshiki Kawamura, Kei Kozawa, Akiko Yoshikawa, Akihiro Ueda, Atsuhiko Ota, Hirohisa Watanabe, Tatsuro Mutoh, Tetsushi Yoshikawa
    Emerging Infectious Diseases 30(12) 2024年12月  
  • 井平 勝, 塩谷 康子, 東本 祐紀, 小澤 慶, 三浦 浩樹, 河村 吉紀, 伊藤 孝一, 齋藤 伸治, 鈴木 光幸, 清水 俊明, 長野 伸彦, 森岡 一朗, 好沢 克, 吉川 哲史
    臨床とウイルス 52(3) 209-209 2024年10月  
  • Kei Kozawa, Yuki Higashimoto, Yoshiki Kawamura, Hiroki Miura, Fumihiko Hattori, Yuka Mihara, Hidetaka Nakai, Naoko Nishimura, Takao Ozaki, Masaru Ihira, Tetsushi Yoshikawa
    Journal of medical virology 96(8) e29847 2024年8月  査読有り筆頭著者責任著者
    To elucidate the seroprevalence and rate of asymptomatic infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Japanese children, serological analysis was performed using serum samples collected from March 2020 to February 2023. A total of 1493 serum samples were collected during the first study period (March 2020 to February 2021). None of the serum samples was positive for SARS-CoV-2 antibody. In the second period (March 2021 to February 2022), seven of the 1055 patients (0.7%) experienced SARS-CoV-2 infection. The third period (March 2022 to February 2023) was divided into three terms: from March to June 30, 2022; from July to October 2022; and from November 2022 to February 2023. The seroprevalence gradually increased throughout this period, with rates of 6.0%, 18.6%, and 30.4% in the three terms, respectively. Pediatric cases of asymptomatic SARS-CoV-2 infection occurred after the surge of Omicron variants. Since none of the SARS-CoV-2 antibody-positive patients had a previous history of coronavirus disease 2019, the seroprevalence rate in this study may represent the rate of asymptomatic infection.
  • Saori Fukuda, Masanori Kugita, Kanako Kumamoto, Yuki Akari, Yuki Higashimoto, Shizuko Nagao, Takayuki Murata, Tetsushi Yoshikawa, Koki Taniguchi, Satoshi Komoto
    Viruses 16(8) 2024年7月25日  査読有り
    The live attenuated human rotavirus vaccine strain RIX4414 (Rotarix®) is used worldwide to prevent severe rotavirus-induced diarrhea in infants. This strain was attenuated through the cell culture passaging of its predecessor, human strain 89-12, which resulted in multiple genomic mutations. However, the specific molecular reasons underlying its attenuation have remained elusive, primarily due to the absence of a suitable reverse genetics system enabling precise genetic manipulations. Therefore, we first completed the sequencing of its genome and then developed a reverse genetics system for the authentic RIX4414 virus. Our experimental results demonstrate that the rescued recombinant RIX4414 virus exhibits biological characteristics similar to those of the parental RIX4414 virus, both in vitro and in vivo. This novel reverse genetics system provides a powerful tool for investigating the molecular basis of RIX4414 attenuation and may facilitate the rational design of safer and more effective human rotavirus vaccines.
  • Yoshiki Kawamura, Kei Kozawa, Goro Koinuma, Tetsuo Onda, Kazutoshi Cho, Yuki Higashimoto, Hiroki Miura, Tetsushi Yoshikawa
    The Pediatric infectious disease journal 2024年2月28日  査読有り
    We encountered a previously healthy 3-year-old girl with interstitial pneumonitis that initially developed due to human adenovirus type 2 infection and exacerbated by primary human herpesvirus 7 infection. A comprehensive serum biomarker analysis showed patterns that differed by viral infection, suggesting that respiratory and lymphotropic viral infections might have different pathophysiology in interstitial pneumonitis.

MISC

 78

書籍等出版物

 3

担当経験のある科目(授業)

 10

共同研究・競争的資金等の研究課題

 12